The phosphoinositide 3-kinase–AKT pathway and the RAS‐MAP kinase cascade enhance cell proliferation and survival, contributing to chemotherapy resistance in lung cancer cells [27, 28]. This evidence concerns the gene AKT1 and lung carcinoma.